Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer.

Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, Bibeau F, Boissière-Michot F, Thezenas S, Cellier D, Azria D, Rouanet P, Senesse P, Ychou M, Lopez-Crapez E.

Pharmacogenomics J. 2011 Dec;11(6):437-43. doi: 10.1038/tpj.2010.62. Epub 2010 Jul 20.

PMID:
20644561
2.

Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.

Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A, Janjan NA, Feig BW.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1098-105.

PMID:
15519780
3.

Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.

Grimminger PP, Danenberg P, Dellas K, Arnold D, Rödel C, Machiels JP, Haustermans K, Debucquoy A, Velenik V, Sempoux C, Bracko M, Hölscher AH, Semrau R, Yang D, Danenberg K, Lenz HJ, Vallböhmer D.

Clin Cancer Res. 2011 May 15;17(10):3469-77. doi: 10.1158/1078-0432.CCR-10-2273. Epub 2011 May 10.

4.

XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.

Grimminger PP, Brabender J, Warnecke-Eberz U, Narumiya K, Wandhöfer C, Drebber U, Bollschweiler E, Hölscher AH, Metzger R, Vallböhmer D.

J Surg Res. 2010 Nov;164(1):e61-6. doi: 10.1016/j.jss.2010.08.002. Epub 2010 Sep 16.

PMID:
20863523
5.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
6.

Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.

Stoehlmacher J, Goekkurt E, Mogck U, Aust DE, Kramer M, Baretton GB, Liersch T, Ehninger G, Jakob C.

Cancer Lett. 2008 Dec 18;272(2):221-5. doi: 10.1016/j.canlet.2008.07.008. Epub 2008 Aug 21.

PMID:
18722050
7.

A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.

Terrazzino S, Agostini M, Pucciarelli S, Pasetto LM, Friso ML, Ambrosi A, Lisi V, Leon A, Lise M, Nitti D.

Pharmacogenet Genomics. 2006 Nov;16(11):817-24.

PMID:
17047490
8.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
9.

Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.

Spindler KL, Nielsen JN, Lindebjerg J, Jakobsen A.

Dis Colon Rectum. 2007 Sep;50(9):1363-9.

PMID:
17661145
10.

Can rectal cancers with pathologic T0 after neoadjuvant chemoradiation (ypT0) be treated by transanal excision alone?

Tulchinsky H, Rabau M, Shacham-Shemueli E, Goldman G, Geva R, Inbar M, Klausner JM, Figer A.

Ann Surg Oncol. 2006 Mar;13(3):347-52. Epub 2006 Feb 1.

PMID:
16450221
11.

Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome.

Moore HG, Shia J, Klimstra DS, Ruo L, Mazumdar M, Schwartz GK, Minsky BD, Saltz L, Guillem JG.

Ann Surg Oncol. 2004 Nov;11(11):955-61. Epub 2004 Oct 15.

PMID:
15525823
12.

Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.

Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW.

J Surg Oncol. 2006 Feb 1;93(2):145-50.

PMID:
16425302
13.

Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?

Kuo LJ, Liu MC, Jian JJ, Horng CF, Cheng TI, Chen CM, Fang WT, Chung YL.

Ann Surg Oncol. 2007 Oct;14(10):2766-72. Epub 2007 Jun 6.

PMID:
17551794
14.

Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region.

Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):500-4. Epub 2006 Jun 6.

PMID:
16757132
15.

Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer.

Frasson M, Garcia-Granero E, Roda D, Flor-Lorente B, Roselló S, Esclapez P, Faus C, Navarro S, Campos S, Cervantes A.

Cancer. 2011 Jul 15;117(14):3118-25. doi: 10.1002/cncr.25866. Epub 2011 Jan 24.

16.

[Predictive factors of tumour response after neoadjuvant chemoradiation for locally advanced rectal cancer and correlation of these factors with survival].

Farnault B, Moureau-Zabotto L, de Chaisemartin C, Esterni B, Lelong B, Viret F, Giovannini M, Monges G, Delpero JR, Bories E, Turrini O, Viens P, Resbeut M.

Cancer Radiother. 2011 Jul;15(4):279-86. doi: 10.1016/j.canrad.2011.01.005. Epub 2011 Apr 22. French.

PMID:
21515083
17.

Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients.

Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD.

J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6.

PMID:
11848629
18.

Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.

Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS.

Radiat Res. 2008 Jul;170(1):49-59. doi: 10.1667/RR1219.1.

PMID:
18582155
19.

Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.

Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR.

Cancer. 2008 Jul 1;113(1):57-64. doi: 10.1002/cncr.23516.

20.

Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy.

Kobayashi H, Hashiguchi Y, Ueno H, Shinto E, Kajiwara Y, Mochizuki H.

Dis Colon Rectum. 2007 Sep;50(9):1354-62.

PMID:
17308999

Supplemental Content

Support Center